JACK MAYE didn’t want to tell anybody. In his freshman year, when he took off his Bedford High School football helmet and ...

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J faces ...

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing USYMRO® to the referen ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hrs [IST] ...

Stelara sales are expected to come down from almost $11 billion in 2023 to around $2.9 billion in 2027, per our estimates. ... which shot up +209%. Free: See Our Top Stock And 4 Runners Up.

In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL ... STEQEYMA full interchangeability with ...

However, despite Stelara LOE, J&J expects growth in the Innovative Medicine segment in 2025 to be driven by its key products ...

However, despite Stelara LOE, J&J expects growth in the Innovative Medicine segment in 2025 to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada as well as new cancer ...

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with p ...